PMID- 25975265
OWN - NLM
STAT- MEDLINE
DCOM- 20160801
LR  - 20220801
IS  - 1865-3774 (Electronic)
IS  - 0925-5710 (Linking)
VI  - 102
IP  - 4
DP  - 2015 Oct
TI  - Persistent complete remission of acute leukemic-phase CCR4-positive gamma-delta 
      peripheral T-cell lymphoma by autologous stem cell transplantation with 
      mogamulizumab.
PG  - 498-505
LID - 10.1007/s12185-015-1805-1 [doi]
AB  - Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), frequently shows 
      a poor outcome. Especially, expressions of CC chemokine receptor 4 (CCR4) and gammadelta 
      T-cell receptor (TCR) are associated with worse prognosis in PTCL-NOS. We here 
      report successful treatment with autologous peripheral blood stem cell 
      transplantation (auto-PBSCT) combined with anti-CCR4 antibody mogamulizumab for a 
      very rare case of CCR4+gammadeltaTCR+ PTCL-NOS that coexisted with Hodgkin's lymphoma. 
      PTCL-NOS in this patient progressed to leukemic phase, whereas Hodgkin's lymphoma 
      disappeared with standard chemotherapies within 4 years of the initial diagnosis. 
      Leukemic-phase PTCL-NOS was refractory to several chemotherapies. However, 
      auto-PBSCT following high-dose chemotherapy combined with pre- and 
      post-transplant mogamulizumab, which is a humanized monoclonal antibody to CCR4, 
      provided persistent complete remission of PTCL-NOS, despite residual gammadeltaTCR+ in 
      the transplanted stem cell product, suggesting a purging effect of mogamulizumab. 
      At 15 months after transplantation, we also found markedly fewer effector 
      regulatory T cells, which may have contributed to prolonged remission. This case 
      suggests that autologous stem cell transplantation combined with mogamulizumab 
      may have a potential to cure T-cell neoplasms that express CCR4 including 
      leukemic-phase PTCL-NOS.
FAU - Furukawa, Miki
AU  - Furukawa M
AD  - Department of Cardiology and Hematology, Fukushima Medical University, 1 
      Hikariga-oka, Fukushima, Fukushima, 960-1295, Japan.
FAU - Ikeda, Kazuhiko
AU  - Ikeda K
AD  - Department of Cardiology and Hematology, Fukushima Medical University, 1 
      Hikariga-oka, Fukushima, Fukushima, 960-1295, Japan. kazu-ike@fmu.ac.jp.
AD  - Department of Transfusion and Transplantation Immunology, Fukushima Medical 
      University, Fukushima, Japan. kazu-ike@fmu.ac.jp.
FAU - Ohkawara, Hiroshi
AU  - Ohkawara H
AD  - Department of Cardiology and Hematology, Fukushima Medical University, 1 
      Hikariga-oka, Fukushima, Fukushima, 960-1295, Japan.
FAU - Saito, Shunichi
AU  - Saito S
AD  - Department of Transfusion and Transplantation Immunology, Fukushima Medical 
      University, Fukushima, Japan.
FAU - Takahashi, Hiroshi
AU  - Takahashi H
AD  - Department of Cardiology and Hematology, Fukushima Medical University, 1 
      Hikariga-oka, Fukushima, Fukushima, 960-1295, Japan.
FAU - Ueda, Koki
AU  - Ueda K
FAU - Matsumoto, Hayato
AU  - Matsumoto H
AD  - Department of Cardiology and Hematology, Fukushima Medical University, 1 
      Hikariga-oka, Fukushima, Fukushima, 960-1295, Japan.
FAU - Hashimoto, Yuko
AU  - Hashimoto Y
AD  - Department of Pathology and Diagnostic Pathology, Fukushima Medical University, 
      Fukushima, Japan.
FAU - Ohto, Hitoshi
AU  - Ohto H
AD  - Department of Transfusion and Transplantation Immunology, Fukushima Medical 
      University, Fukushima, Japan.
FAU - Ogawa, Kazuei
AU  - Ogawa K
AD  - Department of Cardiology and Hematology, Fukushima Medical University, 1 
      Hikariga-oka, Fukushima, Fukushima, 960-1295, Japan.
FAU - Takeishi, Yasuchika
AU  - Takeishi Y
AD  - Department of Cardiology and Hematology, Fukushima Medical University, 1 
      Hikariga-oka, Fukushima, Fukushima, 960-1295, Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20150515
PL  - Japan
TA  - Int J Hematol
JT  - International journal of hematology
JID - 9111627
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (CCR4 protein, human)
RN  - 0 (Receptors, Antigen, T-Cell, gamma-delta)
RN  - 0 (Receptors, CCR4)
RN  - YI437801BE (mogamulizumab)
SB  - IM
EIN - Int J Hematol. 2015 Jul;102(1):147. Udea, Koki [corrected to Ueda, Koki]. PMID: 
      26062726
MH  - Antibodies, Monoclonal, Humanized/*administration & dosage
MH  - Autografts
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/blood/therapy
MH  - Receptors, Antigen, T-Cell, gamma-delta/*blood
MH  - Receptors, CCR4/*antagonists & inhibitors/blood
MH  - Remission Induction
MH  - *Stem Cell Transplantation
OTO - NOTNLM
OT  - Autologous stem cell transplantation
OT  - CCR4
OT  - Mogamulizumab
OT  - Peripheral T-cell lymphoma not otherwise specified
OT  - Purging
EDAT- 2015/05/16 06:00
MHDA- 2016/08/02 06:00
CRDT- 2015/05/16 06:00
PHST- 2015/02/12 00:00 [received]
PHST- 2015/04/30 00:00 [accepted]
PHST- 2015/04/28 00:00 [revised]
PHST- 2015/05/16 06:00 [entrez]
PHST- 2015/05/16 06:00 [pubmed]
PHST- 2016/08/02 06:00 [medline]
AID - 10.1007/s12185-015-1805-1 [pii]
AID - 10.1007/s12185-015-1805-1 [doi]
PST - ppublish
SO  - Int J Hematol. 2015 Oct;102(4):498-505. doi: 10.1007/s12185-015-1805-1. Epub 2015 
      May 15.